By Editor • September 2, 2026 • 1 min read
Trump's new drug pricing deals with biotech firms may not effectively reduce costs, primarily impacting Medicaid but exempting Medicare.
Read moreBy Editor • September 1, 2026 • 1 min read
The Trump administration's announcement of drug pricing deals raises significant unanswered questions about their implications.
Read moreBy Editor • September 1, 2026 • 1 min read
Novartis makes strides in multiple sclerosis treatment with a new BTK inhibitor, while Alumis faces setbacks in lupus trials.
Read moreBy Editor • August 31, 2026 • 1 min read
Trump announces new deals with nine drugmakers to ensure lower prices for U.S. patients and Medicaid programs.
Read moreBy Editor • August 31, 2026 • 1 min read
Bayer, Takeda, and others are part of upcoming drug pricing deals, while the FDA has approved Mimrylo for polycythemia vera.
Read moreBy Editor • August 27, 2026 • 1 min read
The FDA has approved a new pancreatic cancer drug by Revolution Medicines, showing a median survival increase in patients.
Read moreBy Editor • August 18, 2026 • 1 min read
Government workers are facing intensified health care challenges as states approach a crucial deadline for a federal drug pricing program.
Read more
